Lilly and Hims & Hers expand access to Zepbound and Foundayo

Self-pay access through one platform

Under the agreement, patients who receive a prescription from a licensed provider on Hims & Hers can access the same self-pay prices available to any patient without leaving the platform. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound.

The companies said the arrangement combines Lilly’s obesity medicines with Hims & Hers’ consumer health platform. The process includes a consultation, a provider’s clinical assessment, prescription fulfillment when appropriate, and delivery to the patient’s home.

What patients receive from Hims & Hers

Hims & Hers said its weight loss membership experience includes 24/7 access to a care team, nutrition guidance, regular clinical check-ins, and access to the Hims & Hers Weight Loss community. Its technology platform also supports provider outreach, follow-up care, and treatment planning.

The companies said Hims & Hers has never offered compounded copies of Lilly’s GLP-1 medicines and has committed not to do so in the future. They also committed to protecting independent clinical decision-making. Providers on the platform will continue to prescribe the treatment they determine is right for each patient.

Medicines and safety information

Foundayo, also called orforglipron, is described in the announcement as Lilly’s daily oral medicine. Zepbound, which contains tirzepatide, is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who have weight-related medical problems, lose excess body weight and keep it off. The announcement also says Zepbound is used for adults with moderate-to-severe obstructive sleep apnea and obesity to improve their OSA.

Lilly says Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. Its warnings include possible thyroid tumors, severe stomach problems, dehydration leading to kidney problems, gallbladder problems, pancreatitis, serious allergic reactions, and low blood sugar in certain circumstances. Patients are directed to discuss side effects and treatment decisions with their healthcare provider.

Why the agreement matters

Lilly said adults with obesity have shown strong and growing interest in receiving care, including prescription medicines, through telehealth providers. The agreement gives patients who choose Hims & Hers a direct route to Lilly medicines while keeping prescribing decisions with licensed providers.

“At Lilly, we are always looking for new ways to help more people get the medicines they need,” said Ilya Yuffa, Lilly’s executive vice president and president of Lilly USA and Global Customer Capabilities. Hims & Hers co-founder and CEO Andrew Dudum said the companies are helping provide “seamless, personal access to FDA-approved Lilly medicine.”